Fondaparinux: A cornerstone drug in acute coronary syndromes

Figure 1 Mechanism of action of various anticoagulants. LMWH: Low molecular weight heparin.

Figure 2 Secondary efficacy and safety outcomes. Outcomes-based at 30 d and 180 d.

Figure 3 The figure shows comparative major bleeding events with Fondaparinux and Enoxaparin. The major bleeding events were noticed significantly lower as compared to Enoxaparin and thus its use was kindred with less major bleeding across all estimated glomerular filtration rate quartiles. eGFR: Estimated glomerular filtration rate.

Figure 4 Primary composite outcome. Death or reinfarction was significantly lower in the Fondaparinux group compared with the control group at 30 d and at 3 or 6 mo.

Figure 5 The Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies Analysis. Outcomes at 30 d and 180 d. LMWH: Low molecular weight heparin.

Figure 6 Brazilian registry data. Outcomes for bleeding and combined events.